How molecular imaging is speeding up antiangiogenic drug development
Weibo Cai1, Jianghong Rao, Sanjiv S Gambhir
1The Molecular Imaging Program at Stanford, Department of Radiology and Bio-X Program, Stanford University School of Medicine, 1201 Welch Road, P095, Stanford, CA 94305-5484, USA.
Molecular Cancer Therapeutics
|November 24, 2006
Summary
Molecular imaging accelerates drug development by visualizing drug effects in vivo. This review focuses on tumor angiogenesis imaging for antiangiogenic drug development and personalized cancer treatment.
Area of Science:
- Oncology
- Molecular Imaging
- Drug Development
Background:
- Drug development is lengthy (10-15 years).
- Novel drug discovery targets specific molecular pathways.
- Robust molecular imaging is crucial for modern drug development.
Purpose of the Study:
- To review advances in molecular imaging for tumor angiogenesis.
- To highlight molecular targets for antiangiogenic drug development.
- To demonstrate molecular imaging's role in preclinical and clinical antiangiogenic therapy evaluation.
Main Methods:
- Focus on molecular probes and imaging techniques.
- Review of targets including VEGF, VEGFR, integrin α(v)β(3), MMPs, endoglin (CD105), and E-selectin.
- Discussion of whole-body readouts, workload reduction, and individualized treatment monitoring.
Main Results:
- Molecular imaging aids in various drug development stages.
- Enables in vivo assessment of drug efficacy and target engagement.
- Facilitates personalized cancer treatment and dose optimization.
Conclusions:
- Molecular imaging significantly enhances antiangiogenic drug development efficiency.
- Provides a platform for understanding tumor angiogenesis mechanisms.
- Supports both preclinical and clinical evaluation of novel antiangiogenic therapies.
